Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Porton Biologics / 博腾生物

Request full access

Suzhou CGT CDMO twin of Porton Advanced (plasmids, viral vectors, cell therapy)

Suzhou Shi, ChinaFounded 2018Biotech & Life Sciences

About Porton Biologics / 博腾生物

Porton Biologics operates as a subsidiary of Porton Pharma Solutions, a Contract Development and Manufacturing Organization (CDMO) founded in 2005. Porton Biologics itself was established in 2018 and is located in Suzhou Industrial Park, China. The parent company, Porton Pharma Solutions, was co-founded by Chairman and CEO Oliver (Nianfeng) Ju, Hui Chen, and Weiqiang Yang. A significant milestone for Porton Biologics was the closing of a Series A funding round in April 2021, which raised 400 million RMB to be used for the construction and operation of a Phase II commercial production facility.

The company functions as a CDMO platform, providing comprehensive, one-stop drug development and manufacturing services for biologics and conjugates. Its business model is centered on offering end-to-end services that span from early-stage research and preclinical development to clinical trials and commercial production. Porton Biologics serves a global clientele of pharmaceutical companies and biotechs, assisting them in advancing their drug candidates through the clinical pipeline and to the market. Revenue is generated by providing these integrated services for various drug modalities.

The core of Porton Biologics' offering is its integrated service platform for gene and cell therapies, as well as complex biologics. This includes services for plasmids, viral vectors, and various cell therapies. The company's capabilities cover the entire lifecycle, including process development, analytical method development, GMP manufacturing, quality control and release testing, and stability studies. Specifically, their services extend to biologics and conjugates like Antibody-Drug Conjugates (ADCs), Antibody-Oligonucleotide Conjugates (AOCs), and Peptide-Drug Conjugates (PDCs). The platform supports everything from payload-linker process development and manufacturing to conjugation and purification process development, and finally, drug substance and drug product manufacturing, including fill and finish operations.

Source: Dealroom company data

At a glance

Status
Operational
Employees
47
Open positions
None listed
Dealroom signal
42.6/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Aug 2022 $80M $320M HM Capital · State Development & Investment Corporation (SDIC) · CS Capital · Porton Pharma ↗
SERIES AOther financing Apr 2021 $55M $220M Momentum Venture Management · HM Capital · State Development & Investment Corporation (SDIC) · GL Ventures —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Porton Biologics / 博腾生物 website traffic

Latest recorded traffic for Porton Biologics / 博腾生物 is 1.2K monthly website visits, up 144.9% over the last three months. Porton Biologics / 博腾生物's team grew 0% over the past year.

Latest monthly visits1.2K 3-month web change+144.9% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Porton Biologics / 博腾生物 in the Suzhou Shi ecosystem

Live from Dealroom

The Porton Biologics / 博腾生物 office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

13 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A13 investors entered at this stage

  • Momentum Venture Management
  • HM Capital
  • State Development & Investment Corporation (SDIC)
  • GL Ventures
  • Huatai Zijin Investment
  • China Merchants Capital
  • China Merchants Securities
  • China Merchants Group
  • CS Capital
  • Porton Pharma
  • Gortune Investment
  • Fosun Health Capital
  • Momentum Venture Capital
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
4 countries with
team presence
🇨🇳 China80.7%
🇺🇸 United States12.9%
🇮🇳 India3.2%
🇭🇰 Hong Kong3.2%
4 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Porton Biologics / 博腾生物 on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Porton Biologics / 博腾生物’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.